I. Song

发表

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects

K. Dooley, C. Flexner, S. Piscitelli, 2013, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

S. Piscitelli, T. Fujiwara, Y. Lou, 2009, Antimicrobial Agents and Chemotherapy.

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

S. Piscitelli, Y. Lou, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

S. Piscitelli, T. Koshiba, J. Borland, 2013, British journal of clinical pharmacology.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

S. Piscitelli, T. Wajima, P. Patel, 2013, Clinical pharmacology in drug development.

the Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease Inhibitors on Effects of Etravirine Alone and with

S. Piscitelli, Y. Lou, T. Wajima, 2011 .

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers

K. Lasseter, Patrick Martin, J. Murphy, 2019, Journal of clinical pharmacology.

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

S. Piscitelli, B. Sadler, J. Brandt, 2015, British journal of clinical pharmacology.

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

K. Tashima, S. Letendre, S. Piscitelli, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, J. Borland, Shuguang Chen, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects

S. Piscitelli, B. Wynne, N. Arya, 2014, Journal of clinical pharmacology.

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Benjamin Young, J. van Lunzen, J. Rockstroh, 2012, The Lancet. Infectious diseases.

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, P. Patel, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

S. Piscitelli, Apurva Patel, Y. Lou, 2011, The Journal of antimicrobial chemotherapy.

Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients

S. Piscitelli, T. Fujiwara, Y. Lou, 2009 .

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

B. Wynne, N. Arya, T. Eley, 2016, BMC Infectious Diseases.

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

S. Piscitelli, S. Weller, B. Wynne, 2016, European Journal of Clinical Pharmacology.

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study

Grace Chen, I. Song, K. Ilić, 2022, Journal of clinical pharmacology.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

B. Wynne, J. Humphreys, G. Bowers, 2016, Journal of acquired immune deficiency syndromes.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

S. Piscitelli, T. Fujiwara, T. Hawkins, 2011, AIDS.

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

M. Ramgopal, B. Wynne, B. Akil, 2015, Antiviral therapy.

Relative Bioavailability of a Paediatric Granule Formulation of the HIV Integrase Inhibitor Dolutegravir in Healthy Adult Subjects

S. Piscitelli, T. Wajima, P. Patel, 2014, Antiviral therapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals

R. Finkelman, Lan Lan, I. Song, 2020, Drugs in R&D.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

S. Piscitelli, T. Wajima, J. Borland, 2015, The Annals of pharmacotherapy.

Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects

M. Boffito, G. Moyle, P. Hay, 2009, Antimicrobial Agents and Chemotherapy.

M. Boffito, G. Moyle, P. Hay, 2009 .

Immunodeficiency Virus-Infected Subjects 300 Milligrams Twice Daily in Human Abacavir at 600 Milligrams Once Daily and Triphosphate following Administration of in Plasma and Intracellular Carbovir Steady-State Pharmacokinetics of Abacavir

M. Boffito, G. Moyle, P. Hay, 2009 .

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

S. Piscitelli, J. Rubio, D. Wilfret, 2014, European Journal of Clinical Pharmacology.

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

S. Piscitelli, S. Castellino, I. Goljer, 2013, Antimicrobial Agents and Chemotherapy.

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study

Patrick Martin, I. Song, K. Ilić, 2020, Clinical and translational science.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

S. Piscitelli, Y. Lou, T. Wajima, 2011, British journal of clinical pharmacology.

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

S. Piscitelli, Y. Lou, T. Wajima, 2010, Journal of acquired immune deficiency syndromes.

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

S. Piscitelli, J. Rubio, A. Yeo, 2014, Pharmacogenomics.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

M. Rizk, J. Butterton, K. Yee, 2017, Clinical Pharmacokinetics.

Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.

S. Piscitelli, T. Wajima, P. Geoffroy, 2013, Drug and alcohol dependence.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

W. Symonds, J. Borland, I. Song, 2007, Antimicrobial Agents and Chemotherapy.

Summary of Maribavir (SHP620) Drug–Drug Interactions Based on Accumulated Clinical and Nonclinical Data

Patrick Martin, Kefeng Sun, I. Song, 2019, Biology of Blood and Marrow Transplantation.

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients with Cytomegalovirus Infections

Grace Chen, C. Jomphe, Nathalie H. Gosselin, 2022, Transplantation and Cellular Therapy.

Clinical Pharmacology of Maribavir (SHP620): A Comprehensive Overview

Patrick Martin, Kefeng Sun, I. Song, 2019, Biology of Blood and Marrow Transplantation.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeﬁciency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects (cid:1)

W. Symonds, J. Borland, I. Song, 2007 .

Effect of Fosamprenavir-Ritonavir on the Pharmacokinetics of Dolutegravir in Healthy Subjects

S. Piscitelli, T. Wajima, J. Borland, 2014, Antimicrobial Agents and Chemotherapy.

STEADY-STATE PHARMACOKINETICS OF PLASMA ABACAVIR AND INTRACELLULAR CARBOVIR TRIPHOSPHATE FOLLOWING ABACAVIR 600mg ONCE DAILY AND 300mg TWICE DAILY IN HIV-INFECTED SUBJECTS

M. Boffito, G. Moyle, Chris, 2009 .

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)

P. Yeni, F. Maggiolo, F. Pulido, 2010, Journal of the International AIDS Society.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

M. Rizk, J. Butterton, K. Yee, 2017, Clinical Pharmacokinetics.